Hematological Diseases Clinical Trial
— AlloCareOfficial title:
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | December 1, 2026 |
Est. primary completion date | October 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients (age> 18 years) treated with myeloablative or non-myeloablative HSCT 6 month prior and in outpatient follow-up without recurrent disease are eligible for inclusion. Exclusion Criteria: - Patients with recurrence or subsequent malignancy requiring cancer treatment or lack of access to email and the Internet will be excluded. |
Country | Name | City | State |
---|---|---|---|
Denmark | Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Danish Cancer Society |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | EORTC Quality of Life Survivorship Core questionnaire (EORTC-QOL-SURV100) | The QLQ-SURV100 is based on the EORTC Quality of Life core questionnaire (QLQ-C30). Applicable to disease-free cancer survivors. It consists of 100 questions divided over thirteen functional scales (i.e. Physical; Role ; Emotional; and Cognitive functioning; Body image; Symptom awareness; Positive health behavior change; Positive life outlook; Positive impact on behavior towards others; Positive social functioning; Work; Sexual functioning; Global health status), nine symptom scales (i.e. Social isolation; Fatigue; Pain; Sleep problems; Health distress; Negative health outlook; Social interference; Sexual problems), one Symptom checklist assessing chronic side effects of cancer treatments, and twelve single items.
Score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QL represents a high QL, but a high score for a symptom item represents a high level of symptomatology. |
12 months (6, 12, 18 months after treatment with allogeneic stem cell transplantation) | |
Secondary | Modified 7-day Lee Chronic-versus-Host Disease Symptom Scale | Validated questionnaire to measure degree of Graft Versus Host disease. The scale contains 28 items grouped in 7 subscales (skin, eye, mouth, lung, nutrition, energy, and psychological), and a 7 day recall period. Patients report how "bothered" they feel about each symptom over the previous 7 days using a five-point Likert scale from "not at all" to "extremely". range from 0 to 100, with a higher score indicating worse symptoms | 12 months (6, 12, 18 months after treatment with allogeneic stem cell transplantation) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02241031 -
Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia
|
Phase 2/Phase 3 | |
Recruiting |
NCT02240992 -
MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment
|
Phase 2/Phase 3 | |
Completed |
NCT02483325 -
Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
|
Phase 2 | |
Recruiting |
NCT05041933 -
Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting
|
||
Completed |
NCT00675038 -
Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload
|
N/A | |
Active, not recruiting |
NCT03745287 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05505760 -
Testing Content Delivery Models for MomConnect
|
N/A | |
Recruiting |
NCT01160952 -
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT00884364 -
Exercise During Chemotherapy for Patients With Hematological Malignancies
|
Phase 3 | |
Completed |
NCT00892502 -
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
|
N/A | |
Active, not recruiting |
NCT00838643 -
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
N/A | |
Recruiting |
NCT05329649 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
|
Phase 3 | |
Completed |
NCT02661035 -
Allo HSCT Using RIC for Hematological Diseases
|
Phase 2 | |
Enrolling by invitation |
NCT06277479 -
Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study
|
||
Completed |
NCT00956358 -
Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT01344681 -
Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
|
Phase 2 | |
Recruiting |
NCT02083731 -
MSC for Treatment of CMV Infection
|
Phase 2 | |
Recruiting |
NCT02083718 -
Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function
|
Phase 2 | |
Recruiting |
NCT01763086 -
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT01763099 -
Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure
|
Phase 2 |